{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:28:30Z","timestamp":1793118510872,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abrupt cessation of alcohol consumption following hospital admission can induce alcohol withdrawal syndrome. This syndrome is challenging to manage and is associated with considerable morbidity and mortality. Current management of alcohol withdrawal syndrome in Australia is generally titrated benzodiazepine administration. In some regions, phenobarbital is preferred but evidence to support its superiority is weak.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We will conduct a single-center, three-arm, open-label, parallel-group, randomized clinical trial. Our primary objective is to determine the feasibility of embedding a randomized clinical trial within an electronic medical record to compare phenobarbital to single-agent benzodiazepine for patients with alcohol withdrawal. We will screen and randomize 45 patients using the Epic electronic medical record system. Patients will receive either low- or standard-dose intravenous phenobarbital (4 or 8\u00a0mg per kilogram), or usual care (benzodiazepine regimen). The primary outcomes to assess feasibility are usability, screening rates, enrollment rates, and compliance. Secondary outcomes are exploratory and include alcohol withdrawal scale scores, dose of benzodiazepine administered, health utilization, adjuvant drug treatments, and patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>There are limited high quality data evaluating the use of phenobarbital administration for alcohol withdrawal syndrome. Additionally, there is limited data evaluating the embedding of screening, randomization, and administration of a sedative drug within the electronic medical record. Our feasibility trial will establish whether this is possible within our health care system. In this protocol paper we detail how we will embed this trial within the electronic medical record Epic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The study (RMH2024.320 v2 06\/01\/2025) is registered with Australian New Zealand Clinical Trials Registry (ANZCTR)\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=ACTRN12625000320459\" ext-link-type=\"uri\">ACTRN12625000320459<\/jats:ext-link>\n                      . Registered on 17 April 2025. Trial Sponsor: The Royal Melbourne Hospital.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40814-026-01867-x","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:46:04Z","timestamp":1781167564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phenobarbital as an Adjuvant to benzodiazepines when compared to Single-agent benzodiazepine Treatment (usual care) for Alcohol withdrawal syndrome in the intensive care unit (PASTA): a study protocol"],"prefix":"10.1186","volume":"12","author":[{"given":"Haustine Patt","family":"Panganiban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G.","family":"Ricciardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Ankravs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneil","family":"Avasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"MacIsaac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Presneill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Semler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore J.","family":"Iwashyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Deane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"1","key":"1867_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5492\/wjccm.v5.i1.27","volume":"5","author":"AJ Mehta","year":"2016","unstructured":"Mehta AJ. Alcoholism and critical illness: A review. WJCCM. 2016;5(1):27.","journal-title":"WJCCM"},{"key":"1867_CR2","unstructured":"Australian Institute of H, Welfare. Alcohol, tobacco & other drugs in Australia. Web Report. AIHW; 2024."},{"issue":"2","key":"1867_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0972-6748.132914","volume":"22","author":"S Kattimani","year":"2013","unstructured":"Kattimani S, Bharadwaj B. Clinical management of alcohol withdrawal: A systematic review. Ind Psychiatry J. 2013;22(2):100\u20138.","journal-title":"Ind Psychiatry J"},{"issue":"5","key":"1867_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/alcalc\/agv043","volume":"50","author":"JR Maldonado","year":"2015","unstructured":"Maldonado JR, Sher Y, Das S, Hills-Evans K, Frenklach A, Lolak S, et al. Prospective Validation Study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) in Medically Ill Inpatients: A New Scale for the Prediction of Complicated Alcohol Withdrawal Syndrome. Alcohol Alcohol. 2015;50(5):509\u201318.","journal-title":"Alcohol Alcohol"},{"issue":"2","key":"1867_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jama.1997.03550020076042","volume":"278","author":"MF Mayo-Smith","year":"1997","unstructured":"Mayo-Smith MF. Pharmacological Management of Alcohol Withdrawal: A Meta-analysis and Evidence-Based Practice Guideline. JAMA. 1997;278(2):144.","journal-title":"JAMA"},{"issue":"2","key":"1867_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/cem.2019.421","volume":"22","author":"H Langlois","year":"2020","unstructured":"Langlois H, Cormier M, Villeneuve E, Hoffman RS, Longo C, Gosselin S. Benzodiazepine resistant alcohol withdrawal: What is the clinician\u2019s preferred definition? CJEM. 2020;22(2):165\u20139.","journal-title":"CJEM"},{"issue":"Suppl 8","key":"1867_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/epi.12025","volume":"53","author":"W L\u00f6scher","year":"2012","unstructured":"L\u00f6scher W, Rogawski MA. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia. 2012;53(Suppl 8):12\u201325.","journal-title":"Epilepsia"},{"issue":"12","key":"1867_CR8","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s00134-015-4063-z","volume":"41","author":"IJ Zaal","year":"2015","unstructured":"Zaal IJ, Devlin JW, Hazelbag M, Klein Klouwenberg PMC, Van Der Kooi AW, Ong DSY, et al. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Med. 2015;41(12):2130\u20137.","journal-title":"Intensive Care Med"},{"key":"1867_CR9","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2147\/TCRM.S176079","volume":"14","author":"M Shafiekhani","year":"2018","unstructured":"Shafiekhani M, Mirjalili M, Vazin A. Psychotropic drug therapy in patients in the intensive care unit - usage, adverse effects, and drug interactions: a review. Ther Clin Risk Manag. 2018;14:1799\u2013812.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"1867_CR10","first-page":"329","volume":"1","author":"F L\u00f3pez-Mu\u00f1oz","year":"2005","unstructured":"L\u00f3pez-Mu\u00f1oz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat. 2005;1(4):329\u201343.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1867_CR11","volume":"15","author":"Z Umar","year":"2023","unstructured":"Umar Z, Haseeb Ul Rasool M, Muhammad S, Yousaf S, Nassar M, Ilyas U, et al. Phenobarbital and alcohol withdrawal syndrome: a systematic review and meta-analysis. Cureus. 2023;15(1):e33695.","journal-title":"Cureus"},{"issue":"9","key":"1867_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0018578717720310","volume":"52","author":"DA Hammond","year":"2017","unstructured":"Hammond DA, Rowe JM, Wong A, Wiley TL, Lee KC, Kane-Gill SL. Patient Outcomes Associated With Phenobarbital Use With or Without Benzodiazepines for Alcohol Withdrawal Syndrome: A Systematic Review. Hosp Pharm. 2017;52(9):607\u201316.","journal-title":"Hosp Pharm"},{"issue":"4","key":"1867_CR13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/npr2.12347","volume":"43","author":"D Malone","year":"2023","unstructured":"Malone D, Costin BN, MacElroy D, Al-Hegelan M, Thompson J, Bronshteyn Y. Phenobarbital versus benzodiazepines in alcohol withdrawal syndrome. Neuropsychopharmacol Rep. 2023;43(4):532\u201341.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"2","key":"1867_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/10600280251340164","volume":"60","author":"TM Law","year":"2026","unstructured":"Law TM, Roper SL, McKinney A, Starnes C, Rains J, Yune JM, et al. Evaluation of Symptom-Triggered Benzodiazepines Versus Phenobarbital for Alcohol Withdrawal Syndrome in Trauma-Surgical Intensive Care Patients. Ann Pharmacother. 2026;60(2):105\u201314.","journal-title":"Ann Pharmacother"},{"key":"1867_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-09817-8","author":"BA Erfle","year":"2025","unstructured":"Erfle BA, Steel TL, Law AC, Kaufman DA, Hills-Dunlap K, Afshar M, et al. Pharmacological interventions for alcohol withdrawal syndrome among hospitalized adults: a multicenter cohort study. J Gen Intern Med. 2025. https:\/\/doi.org\/10.1007\/s11606-025-09817-8.","journal-title":"J Gen Intern Med"},{"issue":"8","key":"1867_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.28694","volume":"8","author":"BJ Wolpaw","year":"2025","unstructured":"Wolpaw BJ, Oren H, Quinnan-Hostein L, Bradley KA, Johnson NJ, Hallgren KA, et al. Hospital-Wide Implementation, Clinical Outcomes, and Safety of Phenobarbital for Alcohol Withdrawal. JAMA Netw Open. 2025;8(8):e2528694.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1867_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40814-021-00963-4","volume":"8","author":"N Filewod","year":"2022","unstructured":"Filewod N, Hwang S, Turner CJ, Rizvi L, Gray S, Klaiman M, et al. Phenobarbital for the management of severe acute alcohol withdrawal (the PHENOMANAL trial): a pilot randomized controlled trial. Pilot Feasibility Stud. 2022;8(1):14.","journal-title":"Pilot Feasibility Stud"},{"issue":"1","key":"1867_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13063-021-05295-5","volume":"22","author":"A Macnair","year":"2021","unstructured":"Macnair A, Love SB, Murray ML, Gilbert DC, Parmar MKB, Denwood T, et al. Accessing routinely collected health data to improve clinical trials: recent experience of access. Trials. 2021;22(1):340.","journal-title":"Trials"},{"issue":"1","key":"1867_CR19","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.9778\/cmajo.20180096","volume":"7","author":"KA Mc Cord","year":"2019","unstructured":"Mc Cord KA, Ewald H, Ladanie A, Briel M, Speich B, Bucher HC, et al. Current use and costs of electronic health records for clinical trial research: a descriptive study. CMAJ Open. 2019;7(1):E23\u201332.","journal-title":"CMAJ Open"},{"key":"1867_CR20","first-page":"1420","volume":"310","author":"HP Panganiban","year":"2024","unstructured":"Panganiban HP, Nguyen CD, Abdelhamid YA, Ankravs M, Karahalios E, Macisaac C, et al. Feasibility of Embedding a Randomised Clinical Trial (RCT) into an Electronic Medical Record (EMR) for Patients Admitted to an Intensive Care Unit (ICU). Stud Health Technol Inform. 2024;310:1420\u20131.","journal-title":"Stud Health Technol Inform"},{"issue":"12","key":"1867_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.clon.2017.10.003","volume":"29","author":"SE Appleyard","year":"2017","unstructured":"Appleyard SE, Gilbert DC. Innovative Solutions for Clinical Trial Follow-up: Adding Value from Nationally Held UK Data. Clin Oncol (R Coll Radiol). 2017;29(12):789\u201395.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"16","key":"1867_CR22","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.2023.20583","volume":"330","author":"ET Qian","year":"2023","unstructured":"Qian ET, Casey JD, Wright A, Wang L, Shotwell MS, Siemann JK, et al. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial. JAMA. 2023;330(16):1557\u201367.","journal-title":"JAMA"},{"issue":"7","key":"1867_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/CCM.0000000000006255","volume":"52","author":"CD Nguyen","year":"2024","unstructured":"Nguyen CD, Panganiban HP, Fazio T, Karahalios A, Ankravs MJ, MacIsaac CM, et al. A Randomized Noninferiority Trial to Compare Enteral to Parenteral Phosphate Replacement on Biochemistry, Waste, and Environmental Impact and Healthcare Cost in Critically Ill Patients With Mild to Moderate Hypophosphatemia. Crit Care Med. 2024;52(7):1054\u201364.","journal-title":"Crit Care Med"},{"key":"1867_CR24","unstructured":"Council NHaMR. National Statement on Ethical Conduct in Human Research. Council AR, editor. Canberra, Australian Capital Territory: National Health and Medical Research Council; 2023."},{"issue":"2","key":"1867_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"1867_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"4","key":"1867_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004589","volume":"22","author":"AW Chan","year":"2025","unstructured":"Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, et al. SPIRIT 2025 statement: Updated guideline for protocols of randomised trials. PLoS Med. 2025;22(4):e1004589.","journal-title":"PLoS Med"},{"issue":"8","key":"1867_CR28","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/jpen.2527","volume":"47","author":"K Wittholz","year":"2023","unstructured":"Wittholz K, Fetterplace K, Karahalios A, Ali Abdelhamid Y, Beach L, Read D, et al. Beta-hydroxy-beta-methylbutyrate supplementation and functional outcomes in multitrauma patients: A pilot randomized controlled trial. JPEN J Parenter Enteral Nutr. 2023;47(8):983\u201392.","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"4","key":"1867_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/87551225241249407","volume":"40","author":"L Brooks","year":"2024","unstructured":"Brooks L, Reinert JP. Phenobarbital Dosing for the Treatment of Alcohol Withdrawal Syndrome: A Review of the Literature. Journal of Pharmacy Technology. 2024;40(4):186\u201393.","journal-title":"Journal of Pharmacy Technology"},{"issue":"2\u20133","key":"1867_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/j.1552-4604.1978.tb02428.x","volume":"18","author":"CT Viswanathan","year":"1978","unstructured":"Viswanathan CT, Booker HE, Welling PG. Bioavailability of oral and intramuscular phenobarbital. J Clin Pharmacol. 1978;18(2\u20133):100\u20135.","journal-title":"J Clin Pharmacol"},{"key":"1867_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.genhosppsych.2023.10.014","volume":"85","author":"S Stallworth","year":"2023","unstructured":"Stallworth S, Stilley K, Viriyakitja W, Powers S, Parish A, Erkanli A, et al. Evaluation of phenobarbital dosing strategies for hospitalized patients with alcohol withdrawal syndrome. Gen Hosp Psychiatry. 2023;85:155\u201362.","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"1867_CR32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ajem.2009.10.010","volume":"29","author":"GW Hendey","year":"2011","unstructured":"Hendey GW, Dery RA, Barnes RL, Snowden B, Mentler P. A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal. Am J Emerg Med. 2011;29(4):382\u20135.","journal-title":"Am J Emerg Med"},{"issue":"3","key":"1867_CR33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s13181-022-00900-8","volume":"18","author":"P Shah","year":"2022","unstructured":"Shah P, Stegner-Smith KL, Rachid M, Hanif T, Dodd KW. Front-Loaded Versus Low-Intermittent Phenobarbital Dosing for Benzodiazepine-Resistant Severe Alcohol Withdrawal Syndrome. J Med Toxicol. 2022;18(3):198\u2013204.","journal-title":"J Med Toxicol"},{"issue":"2","key":"1867_CR34","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1213\/ANE.0000000000002662","volume":"127","author":"OO Nafiu","year":"2018","unstructured":"Nafiu OO, Mills K, Tremper KK. Some Cautionary Tales About Ideal Body Weight Dosing of Anesthetic Medications: It Is Not All That Ideal! Anesth Analg. 2018;127(2):586\u20138.","journal-title":"Anesth Analg"},{"issue":"Suppl 7","key":"1867_CR35","first-page":"S3","volume":"215","author":"PS Haber","year":"2021","unstructured":"Haber PS, Riordan BC, Winter DT, Barrett L, Saunders J, Hides L, et al. New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. Med J Aust. 2021;215(Suppl 7):S3\u201332.","journal-title":"Med J Aust"},{"issue":"2","key":"1867_CR36","first-page":"29","volume":"8","author":"J Brooke","year":"2013","unstructured":"Brooke J. SUS: a retrospective. J Usability Studies. 2013;8(2):29\u201340.","journal-title":"J Usability Studies"},{"issue":"2","key":"1867_CR37","first-page":"65","volume":"25","author":"MH Northcott","year":"2023","unstructured":"Northcott MH, Johnston G, Presneill JJ, Fazio TN, Adamson N, Ankravs MJ, et al. Aggression, violence and threatening behaviour during critical illness. Crit Care Resusc. 2023;25(2):65\u201370.","journal-title":"Crit Care Resusc"},{"issue":"4","key":"1867_CR38","first-page":"249","volume":"26","author":"MJ Ankravs","year":"2024","unstructured":"Ankravs MJ, Udy A, Bellomo R, Presneill JJ, Adams L, Abdelhamid YA, et al. Olanzapine versus quetiapine in critically ill patients with hyperactive delirium: Protocol for a multicentre, cluster-randomised, double-crossover, pragmatic clinical trial (CALM-ICU). Crit Care Resusc. 2024;26(4):249\u201354.","journal-title":"Crit Care Resusc"},{"issue":"7","key":"1867_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4521","volume":"1","author":"PD Tyler","year":"2018","unstructured":"Tyler PD, Du H, Feng M, Bai R, Xu Z, Horowitz GL, et al. Assessment of Intensive Care Unit Laboratory Values That Differ From Reference Ranges and Association With Patient Mortality and Length of Stay. JAMA Netw Open. 2018;1(7):e184521.","journal-title":"JAMA Netw Open"},{"key":"1867_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083405","volume":"390","author":"X Ying","year":"2025","unstructured":"Ying X, Freedland KE, Powell LH, Stuart EA, Ehrhardt S, Mayo-Wilson E. Determining sample size for pilot trials: a tutorial. BMJ. 2025;390:e083405.","journal-title":"BMJ"},{"key":"1867_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40814-019-0423-8","volume":"5","author":"L Thabane","year":"2019","unstructured":"Thabane L, Lancaster G. A guide to the reporting of protocols of pilot and feasibility trials. Pilot Feasibility Stud. 2019;5:37.","journal-title":"Pilot Feasibility Stud"},{"issue":"1","key":"1867_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40814-023-01291-5","volume":"9","author":"K Mellor","year":"2023","unstructured":"Mellor K, Albury C, Dutton SJ, Eldridge S, Hopewell S. Recommendations for progression criteria during external randomised pilot trial design, conduct, analysis and reporting. Pilot Feasibility Stud. 2023;9(1):59.","journal-title":"Pilot Feasibility Stud"},{"key":"1867_CR43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s40814-019-0500-z","volume":"5","author":"L Mbuagbaw","year":"2019","unstructured":"Mbuagbaw L, Kosa SD, Lawson DO, Stalteri R, Olaiya OR, Alotaibi A, et al. The reporting of progression criteria in protocols of pilot trials designed to assess the feasibility of main trials is insufficient: a meta-epidemiological study. Pilot Feasibility Stud. 2019;5:120.","journal-title":"Pilot Feasibility Stud"},{"issue":"5","key":"1867_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40263-014-0163-5","volume":"28","author":"EC Perry","year":"2014","unstructured":"Perry EC. Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs. 2014;28(5):401\u201310.","journal-title":"CNS Drugs"},{"issue":"1","key":"1867_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5507\/bp.2013.089","volume":"159","author":"B Mainerova","year":"2015","unstructured":"Mainerova B, Prasko J, Latalova K, Axmann K, Cerna M, Horacek R, et al. Alcohol withdrawal delirium - diagnosis, course and treatment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(1):44\u201352.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"1","key":"1867_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00540-012-1458-7","volume":"27","author":"MT Johnson","year":"2013","unstructured":"Johnson MT, Yamanaka TT, Fraidenburg DR, Kane SP. Benzodiazepine misadventure in acute alcohol withdrawal: the transition from delirium tremens to ICU delirium. J Anesth. 2013;27(1):135\u20136.","journal-title":"J Anesth"},{"issue":"4","key":"1867_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-015-0358-1","volume":"75","author":"A Mirijello","year":"2015","unstructured":"Mirijello A, D\u2019Angelo C, Ferrulli A, Vassallo G, Antonelli M, Caputo F, et al. Identification and management of alcohol withdrawal syndrome. Drugs. 2015;75(4):353\u201365.","journal-title":"Drugs"},{"issue":"3","key":"1867_CR48","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jemermed.2012.07.056","volume":"44","author":"J Rosenson","year":"2013","unstructured":"Rosenson J, Clements C, Simon B, Vieaux J, Graffman S, Vahidnia F, et al. Phenobarbital for Acute Alcohol Withdrawal: A Prospective Randomized Double-blind Placebo-controlled Study. J Emerg Med. 2013;44(3):592-8.e2.","journal-title":"J Emerg Med"},{"issue":"8","key":"1867_CR49","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0196-0644(87)80520-6","volume":"16","author":"GP Young","year":"1987","unstructured":"Young GP, Rores C, Murphy C, Dailey RH. Intravenous phenobarbital for alcohol withdrawal and convulsions. Ann Emerg Med. 1987;16(8):847\u201350.","journal-title":"Ann Emerg Med"},{"issue":"5","key":"1867_CR50","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/acem.14788","volume":"31","author":"K Punia","year":"2024","unstructured":"Punia K, Scott W, Manuja K, Campbell K, Balodis IM, MacKillop J. SAEM GRACE: Phenobarbital for alcohol withdrawal management in the emergency department: A systematic review of direct evidence. Acad Emerg Med. 2024;31(5):481\u201392.","journal-title":"Acad Emerg Med"},{"issue":"5","key":"1867_CR51","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jpsychires.2010.10.008","volume":"45","author":"AC Leon","year":"2011","unstructured":"Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011;45(5):626\u20139.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"1867_CR52","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40814-025-01675-9","volume":"11","author":"R Montgomery","year":"2025","unstructured":"Montgomery R. Sample size justification in feasibility studies: moving beyond published guidance. Pilot Feasibility Stud. 2025;11(1):88.","journal-title":"Pilot Feasibility Stud"},{"issue":"1","key":"1867_CR53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13063-024-07956-7","volume":"25","author":"KM Turner","year":"2024","unstructured":"Turner KM, Huntley A, Yardley T, Dawson S, Dawson S. Defining usual care comparators when designing pragmatic trials of complex health interventions: a methodology review. Trials. 2024;25(1):117.","journal-title":"Trials"},{"issue":"1","key":"1867_CR54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/17407745231195094","volume":"21","author":"VJ Ford","year":"2024","unstructured":"Ford VJ, Klein HG, Danner RL, Applefeld WN, Wang J, Cortes-Puch I, et al. Controls, comparator arms, and designs for critical care comparative effectiveness research: It\u2019s complicated. Clin Trials. 2024;21(1):124\u201335.","journal-title":"Clin Trials"}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-026-01867-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-026-01867-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-026-01867-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:02:16Z","timestamp":1787050936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40814-026-01867-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1186\/s40814-026-01867-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7521474\/v1","asserted-by":"object"}]},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol has been approved by the Royal Melbourne Hospital Research Ethics Committee (RMH2024.320 HREC114383). Participants will be included under emergency treatment with an opt-out process for retention of data. The trial has been registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12625000320459).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to the publication of the protocol manuscript. No restrictions have been placed on the publication of future data resulting from the trial.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"119"}}